Patent Discloses New Approach to Cancer Treatment Using Immunotherapy

Researchers at Teclison Inc. have made a significant breakthrough in cancer treatment with a new patent that discloses a method of enhancing an immune response against solid tumors. The method combines the use of hypoxia-activated bioreductive agents (HABAs) with immune checkpoint inhibitors to stimulate the immune system to attack cancer cells. This innovative approach has the potential to improve treatment outcomes for patients with various types of cancer.

According to the patent, the method involves administering a HABA to the patient, inducing hypoxia in the tumor by embolizing blood vessels supplying the tumor, and then administering an immune checkpoint inhibitor to enhance the immune response. The HABA used in the method is tirapazamine, a bioreductive agent that is activated under hypoxic conditions. The immune checkpoint inhibitor used is nivolumab or pembrolizumab, a monoclonal antibody that blocks the activity of PD-1, a protein that prevents the immune system from attacking cancer cells.

The patent claims that the method has several benefits, including:

• Enhancing an immune response against a solid tumor
• Increasing immune system exposure to tumor antigens
• Improving treatment outcomes for patients with various types of cancer, including liver cancer, lung cancer, and breast cancer

The method has shown promising results in preclinical studies, with a synergistic effect observed between the HABA and immune checkpoint inhibitor in treating cancer.

Key Takeaways:

• The patent discloses a new method of treating cancer using immunotherapy that combines HABAs with immune checkpoint inhibitors to stimulate the immune system to attack cancer cells.
• The method involves administering a HABA to the patient, inducing hypoxia in the tumor, and then administering an immune checkpoint inhibitor to enhance the immune response.
• The HABA used in the method is tirapazamine, a bioreductive agent activated under hypoxic conditions.
• The immune checkpoint inhibitor used is nivolumab or pembrolizumab, a monoclonal antibody that blocks the activity of PD-1.
• The method has been shown to have several benefits, including enhancing an immune response against a solid tumor, increasing immune system exposure to tumor antigens, and improving treatment outcomes for patients with various types of cancer.
• The method has shown promising results in preclinical studies, with a synergistic effect observed between the HABA and immune checkpoint inhibitor in treating cancer.
• The HABA and immune checkpoint inhibitor can be used alone or in combination to treat a variety of cancers, including liver cancer, lung cancer, and breast cancer.

Statistics:

• The HABA used in the method is tirapazamine, which is a bioreductive agent activated under hypoxic conditions.
• The immune checkpoint inhibitor used is nivolumab or pembrolizumab, which is a monoclonal antibody that blocks the activity of PD-1.
• The method has been shown to be effective in treating various types of cancer, including liver cancer, lung cancer, and breast cancer.
• The method has a synergistic effect with the immune checkpoint inhibitor in treating cancer.
• The HABA and immune checkpoint inhibitor can be used alone or in combination to treat a variety of cancers.

Sources:

• Lee, Ruey-min. Compositions and methods for immune-mediated cancer therapy. U.S. Patent Number 12350275, filed November 21, 2022, and published online on July 8, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(12350275)&db=USPAT&type=ids